⌕
Amphastar Pharmaceuticals · AMPH · Nasdaq
Tenet 67 · Solid
Compare
$29.10−0.24%At closeTenet 67 · Solid
$29.10−0.07 (−0.24%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Amphastar Pharmaceuticals (AMPH) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AMPH's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 11, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London

RANCHO CUCAMONGA, Calif., Nov. 11, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating …

AMPH −0.2% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 18:04 ET
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Exe…

AMPH −0.2% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 19:31 ET
Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year…

AMPH −0.2% todayRead at source ↗
● MarketBeatNov 5, 2026 · 19:15 ET
Amphastar Pharmaceuticals Q3 Earnings Call Highlights

Amphastar Pharmaceuticals NASDAQ: AMPH reported record third-quarter revenue of $207.6 million, up 8% from a year earlier, as sales of BAQSIMI and Primatene MIST and contributions from newer products offset manufacturing…

AMPH −0.2% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 18:46 ET
Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.93 per share a year ago.…

AMPH −0.2% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 16:10 ETCOMPANY'S OWN WORDS
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Net revenues of $207.6 million for the three months ended September 30, 2026 GAAP net income of $37.8 million, or $0.87 per share, for the third quarter Adjusted non-GAAP net income of $49.3 million, or $1.14 per share, …

AMPH −0.2% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 11:06 ET
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

AMPH −0.2% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026

RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, afte…

AMPH −0.2% todayRead at source ↗
● Zacks Investment ResearchOct 6, 2026 · 10:41 ET
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

AMPH −0.2% todayRead at source ↗
● Defense WorldOct 6, 2026 · 10:14 ET
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two compa…

AMPH −0.2% todayRead at source ↗
● Defense WorldSep 30, 2026 · 06:28 ET
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of “Reduce” from Analysts

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) has been given a consensus recommendation of "Reduce" by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two investment an…

AMPH −0.2% todayRead at source ↗
● Defense WorldSep 20, 2026 · 05:09 ET
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an a…

AMPH −0.2% todayRead at source ↗
● PRNewsWireSep 1, 2026 · 06:00 ETCOMPANY'S OWN WORDS
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be pre…

AMPH −0.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just AMPH · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.